1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Zhejiang Orient Gene Biotech Co., Ltd. Class A

Zhejiang Orient Gene Biotech Co., Ltd. Class A

SSSE:688298
18.01
CNY
+0.26
(+1.46%)
3.60BMarket Cap
Zhejiang Orient Gene Biotech Co., Ltd. Class A
SSE:688298
(Shanghai Stock Exchange)

Recent

price

18.01

P/E

ratio

- -

div

yld

0.12%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.9
1.48
1.9
2.42
16.55
70.62
52.2
4.06
4.21
4.92
- -
Revenue per Share
0.18
0.22
0.43
0.54
8.5
34.17
12.31
-1.97
-2.69
-2.98
- -
Basic EPS, GAAP
0.04
0.13
0.17
0.28
8.43
32.61
11.57
-13.09
-6.47
-2.61
- -
Free Cash Flow per Basic Share
0.03
0.03
0.02
0.22
0.13
3.5
4.42
1.74
0.08
0.03
0.02
Dividend per Share
0.65
0.88
1.33
1.66
12.13
34.01
40.49
36.89
32.96
29.73
28.55
Book Value per Share
0.58
0.82
1.26
1.57
12.06
33.38
38.1
34.51
29.53
25.34
24.31
Tangible Book Value per Share
202
151
150
152
197
144
168
202
197
192
191
Basic Weighted Avg Shares
182
224
286
367
3,265
10,169
8,768
820
828
947
- -
Sales/Revenue/Turnover
24.75
23.04
25.91
25.71
65.06
57.84
35.6
-52.21
-76.43
-47.17
- -
Operating Margin (%)
5
5
5
6
7
37
87
165
206
196
- -
Depreciation Expense
36
33
65
82
1,677
4,920
2,068
-398
-529
-574
- -
Net Income, GAAP
18.65
17.86
16.94
15.1
14.89
14.37
15.11
- -
- -
- -
- -
Effective Tax Rate (%)
19.55
14.88
22.87
22.35
51.37
48.38
23.58
-48.48
-63.9
-60.55
- -
Profit Margin (%)
32
63
122
168
2,203
6,068
6,469
4,810
2,775
2,424
2,125
Working Capital
- -
- -
- -
7
3
13
79
344
47
184
124
LT Debt
99
138
208
254
2,451
6,889
8,323
7,550
6,791
6,086
5,841
Total Equity
- -
16.09
27.03
28.41
110.11
96.34
26.95
- -
- -
- -
- -
Return on Invested Capital (%)
- -
20.18
30.88
32.69
122.33
104.67
26.7
- -
- -
- -
- -
Return on Capital (%)
- -
28.73
39.08
36.27
124.36
105.78
27.53
-5.1
-7.51
-9.08
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
142
256
320
LT Borrowings
159
45
104
LT Finance Leases
25
25
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
202
202
202
Market Capitalization
4,723
4,596
3,601

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,256
3,038
3,017
Cash, Cash Equivalents & STI
2,572
2,400
2,387
Accounts Receivable, Net
213
178
166
Inventories
310
294
292
Total Current Liabilities
832
802
892
Payables & Accruals
- -
- -
- -
ST Debt
142
256
320
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.42%
-10.39%
Free Cash Flow
- -
-44.92%
-60.58%
Net Income, GAAP
- -
11.52%
8.43%
Sales/Revenue/Turnover
- -
24.48%
14.43%
Total Cash Common Dividend
- -
347.04%
-59.64%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
183
235
239
170
828
2025
192
211
- -
276
947
2026
256
208
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.33
-0.43
-0.57
-1.38
-2.69
2025
-0.57
-0.25
- -
-1.89
-2.98
2026
-0.49
-0.67
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.03
0.08
2025
0.01
0.01
- -
0.01
0.03
2026
0.01
0.01
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Zhejiang Orient Gene Biotech Co., Ltd Zhejiang Orient Gene Biotech Co., Ltd researches, develops, manufactures and sells in-vitro diagnostic products principally focused on point-of-care testing (POCT) rapid diagnostic reagents; its core offerings include infectious disease tests such as COVID-19 antigen, IgG/IgM antibody, influenza, RSV and adenovirus combo kits, drugs of abuse detection panels, pregnancy and fertility tests including HCG strips, cardiac markers like troponin and CK-MB, tumor markers such as PSA and CEA, autoimmunity assays, non-infectious disease diagnostics, food safety tests and animal health products; the company also provides immunological fluorescence analyzer (IFA) solutions, quantum-beads flowcytometry systems for HPV, tumor markers, cardiac markers, allergy, cytokines and infections, dry biochemical strips, molecular diagnostics, FISH probes, raw materials and supporting instruments including analyzers. Zhejiang Orient Gene Biotech Co., Ltd operates three core platforms encompassing POCT rapid diagnostics, molecular diagnostics and liquid biochips, with infectious disease and toxicology comprising its flagship series that account for the majority of sales; approximately 95% of products are exported to over 100 countries across North America, South America, Europe, Asia, Africa and Oceania, serving healthcare providers, laboratories, third-party testing services and end-users globally. Founded in December 2005 and headquartered in Anji, Zhejiang Province, China, the company listed on the Shanghai Stock Exchange STAR Market (ticker: 688298.SS) in February 2020 and maintains subsidiaries including Healgen Scientific LLC and Healstone Biotech Inc. in the US, Qingdao Handsen Biotechnology Co., Ltd. and others in China; it employs around 2,276 people and holds provincial high-tech enterprise status with a complete industry chain from raw materials to instruments. Recent developments include the May 2025 EU IVDR certification for its COVID-19/Flu A&B/RSV/Adeno antigen combo test kit, showcasing expansion in multi-pathogen respiratory diagnostics; in May 2025, the company highlighted global respiratory testing advancements at industry events, and in February 2025 participated in MEDLAB Dubai to promote innovative products; ongoing efforts focus on industrial upgrading toward third-party testing services, sustained R&D investment at around 3% of revenue and stable partnerships with gene sequencing firms and research institutions like Zhejiang University.